Journal article

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

DL Bhatt, KAA Fox, W Hacke, PB Berger, HR Black, WE Boden, P Cacoub, EA Cohen, MA Creager, JD Easton, MD Flather, SM Haffner, CW Hamm, GJ Hankey, SC Johnston, KH Mak, JL Mas, G Montalescot, TA Pearson, PG Steg Show all

NEW ENGLAND JOURNAL OF MEDICINE | MASSACHUSETTS MEDICAL SOC | Published : 2006

Abstract

BACKGROUND: Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events. METHODS: We randomly assigned 15,603 patients with either clinically evident cardiovascular disease or multiple risk factors to receive clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day) or placebo plus low-dose aspirin and followed them for a median of 28 months. The primary efficacy end point was a composite of myocardial infarction, stroke, or death from cardiovascular causes. RESULTS: The rate of the primary efficacy end point was 6.8 percent with clopidogrel plus aspirin and 7.3 percent with pl..

View full abstract